Tarsus is a late-stage biopharmaceutical company focused on developing therapies for ophthalmology conditions.
Tarsus’ lead pipeline candidate, TP-03, is attempting to treat Demodex blepharitis. This treatment has completed four phase 2 trials to date. It expects to launch a phase 2b/3 trial in September.
Tarsus was founded in 2016.
More articles on surgery centers:
12-OR ASC part of $295M Florida orthopedic hospital expansion
3 ASCs launching total joint programs
4 ASCs installing total joint robots
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
